STRO Stock Forecast & Price Target
STRO Analyst Ratings
Bulls say
Sutro Biopharma Inc. has demonstrated promising advancements in its product pipeline, particularly with STRO-004 showcasing improved safety and anti-tumor activity compared to existing treatments, which supports a strong potential for clinical success. The company is undergoing a significant workforce reduction of approximately 50% and will externalize its cell-free manufacturing capabilities, aligning with a strategy aimed at long-term growth and financial sustainability through 2026. Furthermore, the anticipated decrease in operating expenses by 50-70%, along with innovative product characteristics, positions Sutro favorably within the biopharmaceutical sector.
Bears say
Sutro Biopharma faces significant risks impacting its financial outlook, primarily stemming from potential underperformance of its lead antibody-drug conjugate (ADC) candidates, which could lead to reduced market penetration and longer timelines for drug approvals. The company reported a net loss of $227.4 million for FY24, equating to a loss of $2.96 per share, and its cash reserves decreased from $388.3 million to $316.9 million within a three-month period, indicating possible liquidity concerns amid ongoing developmental challenges. Additionally, the decision to implement a near-50% headcount reduction and the discontinuation of the luvelta program, once a pivotal aspect of Sutro's portfolio, raises further doubts about the company’s strategic direction and ability to deliver value to shareholders.
This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.
STRO Analyst Forecast & Price Prediction
Start investing in STRO
Order type
Buy in
Order amount
Est. shares
0 shares